(1S,3S)-3-azaniumylcyclohexane-1-carboxylate | 933445-54-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,3S)-3-azaniumylcyclohexane-1-carboxylate
• CAS: 933445-54-6
• 化学式: C7H13NO2
• 分子量: 143.18
• InChiKey: CKTUXQBZPWBFDX-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  氯化亚砜 、 (1S,3S)-3-azaniumylcyclohexane-1-carboxylate 、 甲醇 在 碳酸氢钠 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 作用下， 以to afford 400 mg (90.9%) of trans-methyl 3-aminocyclohexanecarboxylate as colorless liquid的产率得到methyl (1S,3S)-3-aminocyclohexane-1-carboxylate
  参考文献：
  名称：

  Inhibitors of protein kinases

  摘要：

  通式（I）的化合物：其中R1、R2、R3、Ra、A、B和x的定义如下，是特别针对细胞周期依赖性激酶家族和/或糖原合成酶激酶3家族的抑制剂，可用于预防和/或治疗任何类型的疼痛、炎症性疾病、癌症、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病、代谢性疾病、肾脏疾病、神经和神经精神疾病以及神经退行性疾病。

  公开号：

  US20110224225A1

文献信息

• 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
  申请人：MSD Oss B.V.

  公开号：EP2548877A1

  公开（公告）日：2013-01-23

  The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

  本发明提供了根据式I提供的6-5成员融合吡啶环化合物或其药学上可接受的盐。 或其药学上可接受的盐，或包含这些化合物的药物组合物以及它们在治疗中的使用。具体而言，本发明涉及在治疗布鲁顿氏酪氨酸激酶（Btk）介导的疾病中使用6-5成员融合吡啶环化合物。
• RHO KINASE INHIBITORS
  申请人：Bosanac Todd

  公开号：US20080161297A1

  公开（公告）日：2008-07-03

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  揭示了一种新颖的取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物，可用作Rho激酶的抑制剂，用于治疗通过Rho激酶活性介导或维持的各种疾病和疾病，包括心血管疾病，包含这些化合物的药物组合物，使用这些化合物的方法以及制备这些化合物的方法。
• METHODS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125902A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及用于确定肾小球滤过率或评估患者肾功能的系统和方法。该方法包括向患者施用化合物I的吡嗪类化合物，并监测患者的肾脏从患者的全身循环中排除吡嗪的速率。当暴露于电磁辐射时，吡嗪化合物会发出荧光，使用一个或多个传感器来检测。患者体内荧光减少的速率被用来计算患者的肾小球滤过率。
• COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125901A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及确定肾小球滤过率或评估需要的患者的肾功能的系统和方法。该系统包括计算设备、电源、一个或多个传感器，以及至少一种示踪剂，当暴露于电磁辐射时发出荧光。传感器检测电磁辐射，患者体内荧光减弱的速率用于计算患者的肾小球滤过率。
• Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0361365A1

  公开（公告）日：1990-04-04

  Compounds of the formula wherein X is inhibit the action of neutral endopeptidase. As a result, such compounds produce diuresis, natriuresis, and lower blood pressure as well as being useful in the treatment of congestive heart failure, relieving pain, and diarrhea when administered to a mammalian host.

  其中X的化合物抑制中性内肽酶的作用。因此，这些化合物产生利尿、排钠和降低血压的效果，同时在治疗充血性心力衰竭、缓解疼痛和腹泻时对哺乳动物宿主有用。